Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program.
Barry
M J
MJ
Medical Practices Evaluation Center, Massachusetts General Hospital, Boston 02114, USA.
Fleming
C
C
Coley
C M
CM
Wasson
J H
JH
Fahs
M C
MC
Oesterling
J E
JE
D000368:Aged; D003362:Cost-Benefit Analysis; D006801:Humans; D008297:Male; D006278:Medicare / Q000191:economics*; D008962:Models, Theoretical; D015397:Program Evaluation; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology; D012306:Risk; D013997:Time Factors; D014481:United States
D017430:Prostate-Specific Antigen